Investment Intelligence Workstation
Baseline Fabric Moderate risk persona
Active Workspace
Marchi Family
Julio Marchi Long-Term Growth
Watchlists › Quality Compounders Radar › NVDA

Thesis Refresh

Refresh the live thesis, posture, and review state for NVDA without leaving the surrounding evidence, plan, and report context.

Opened from the review queue. Saving this thesis refresh returns to the queue and marks the originating queue item completed for today only when the current queue key and signature still match an active item.
Current Posture
Waiting
Review Status
Current
Review Date
Mar 5, 2025
Evidence Trail
3 notes linked to this asset

Thesis Decision

Keep the decision record explicit here. Use the side panels when the thesis needs evidence context, operating-plan thresholds, or a deeper report review before the next action.

Core Thesis

Operator Note

Optional. If you fill this in, a concise thesis-review entry is added to the durable review log using the review date above.

Back to Watchlist

Evidence Snapshot

3 research notes on file

View All + Add Note
Thesis Risk Apr 1, 2026
Chip Export Controls Limit Addressable Market

US export restrictions on H100/H100-equivalent chips to China and other restricted markets reduce the addressable market. NVIDIA has released compliant variants (H800, A800) but with reduced specifications.

Thesis Support Mar 1, 2026
Data Center Revenue Now Dominant Business Line

NVIDIA Data Center segment represents ~85% of total revenue in FY2026, driven by H100 and H200 demand from hyperscalers and sovereign AI programs.

Competitive Insight Feb 15, 2026
AMD MI300X Gaining Inference Workload Share at Margin

AMD MI300X is winning inference-specific workloads at select hyperscalers. NVIDIA still dominates training workloads. Inference share competition is the medium-term watch.

Operating Plan
Edit Plan
Treat NVDA as a momentum-sensitive compounder: wait for controlled digestion or trim into another vertical extension.
At trim target Mapped to latest ingested price $136.66
$118.00 $136.66
Invalidate $118.00 Entry Low $125.00 Entry High $132.00 Trim $135.00 Current $136.66
Entry: +3.5% above zone Trim: +1.2% above target Risk: +13.7% cushion
Review May 5, 2026 27 days overdue Cadence 14d
Entry Zone $125.00 - $132.00
Trim $135.00
Invalidate $118.00
Monitor: Check hyperscaler capex signals and Blackwell supply commentary at the next review.
Execution: Do not add above the trim line without a fresh thesis review; use any trim to recycle into lower-beta AI exposure.

Recent Reviews

No review-log entries are recorded yet for this item. Open the full review log flow when you need a longer decision record.